In the June issue of the Journal of Drugs in Dermatology, authors Joel Schlessinger MD, et al, shared the outcomes a pilot study of a potential new treatment for erythematotelangiectatic rosacea: microfocused ultrasound (MFU-V).
The researchers treated 91 patients, who had been diagnosed with erythematotelangiectatic rosacea (Clinician Erythema Assessment (CEA) score ≥3 and Patient Self-Assessment (PSA) erythema score ≥2). Subjects were randomized to receive one or two low-density MFU-V treatments or one or two high-density MFU-V treatments. The researchers defined treatment success as a 1-point change at 90-days post treatment.
At 90-days post treatment 75 percent to 93 percent of subjects across all four treatment groups achieved success. The highest rate of safety and efficacy was seen in the group that underwent one high-density MFU-V treatment. Adverse events included bruising (44 pecent), tenderness/soreness (43 percent) and redness (35 percent).
Based on the results of the study, the authors conclude that a large, randomized, controlled study of single-session MFU-V treatment for erythematotelangiectatic rosacea is warranted.
Image copyright iStock.com/Lipowski
